.Sidney Kimmel Cancer Center – Jefferson Health's Andrew Chapman: 'This is the classic Philadelphia story. We were underdogs. No one at the beginning would’ve thought that this was likely going to happen.'
cancerletter.com/conversation-w…

“This is our time, and the time is now”—Chapman tells us about Jefferson’s (Sidney Kimmel Cancer Center – Jefferson Health) final push for Comprehensive designation.
cancerletter.com/conversation-w…

Leading a Comprehensive Cancer Center—one job or two? Guest editorial by George Weiner (George Weiner).
cancerletter.com/guest-editoria…

Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion. Guest editorial by Kimlin Tam Ashing, Nadine J. Barrett, PhD, MA., MS, Kim F. Rhoads, Folakemi T. Odedina, Dr. Hayley S. Thompson, and camille ragin.
cancerletter.com/guest-editoria…

Surviving lung cancer focused Morhaf Al Achkar’s (Morhaf Al Achkar) career on addressing health disparities. cancerhistoryproject.com/article/surviv…

What led Edward Copeland to specialize in surgical oncology? 'If you want to cure somebody, that’s the specialty you go into, because virtually everybody you operate on who has a malignancy, you’re operating for cure.' American College of Surgeons
cancerletter.com/in-the-archive…

Kimryn Rathmell (Dr. Kimryn Rathmell): 'We’re really thinking hard about how we make sure that cancer research gets done, wherever it gets done, is good for us. So we’re not saying it all has to happen in National Cancer Institute, it just has to happen.'
cancerletter.com/nci-director-r…

'Although the passing of Dr. Copeland is a profound loss for both the field of surgery and the University of Florida, I am committed to honoring his memory by making surgical organizations and the UF Surgery the best they can be.' - Gilbert R. Upchurch Jr
cancerletter.com/obituary/20240…

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows.
cancerletter.com/clinical-round…

.Hilary Robbins (@IARCWHO): “If we care about cancer mortality as the gold standard, if we are trying to reduce the frequency with which people die from cancer, it’s really difficult to use these studies to say something about that.'
cancerletter.com/clinical/20240…

.The James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control.
cancerletter.com/in-brief/20240…

'Other conference sessions covered a range of topics of interest to cancer center administrators, such as fostering connections between Cancer Research Training & Education Coordination, Community Outreach & Engagement, & the Plan to Enhance Diversity.'
cancerletter.com/guest-editoria…

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data.
cancerletter.com/clinical-round…

The results from the just-published IARC analysis suggest that these trials, after years of study and millions of dollars in investment, may not determine with any certainty whether these MCDs save lives.
cancerletter.com/clinical/20240…

The institute’s (National Cancer Institute) new paylines for fiscal year 2024 reflect the constraints of a reduced budget—additionally, noncompeting grants, also known as continuing grants, will be funded at 95% of the committed level, a 3% drop compared to the FY23 level.
cancerletter.com/nci-director-r…

Nancy Hanley Eriksson, Kevin Conroy receive TGen’s John S. McCain Leadership Awards.
cancerletter.com/in-brief/20240…

'Described by his colleagues as a masterful clinician and quintessential role model for the academic surgeon, Copeland was a distinguished surgeon, patient care advocate, and leader in the surgical community.'
cancerletter.com/obituary/20240…

DOD Lung Cancer Research Program funding opportunities for FY24.
cancerletter.com/funding-opport…

In 2025, the CEL team will host an event to hear and learn diverse perspectives across the cancer community to further advance NCI’s health equity efforts.
cancerletter.com/health-equity/…

Matt Kalaycio named chair of board of directors at National Comprehensive Cancer Network (NCCN).
cancerletter.com/in-brief/20240…